What's new

EMEA-002432-PIP02-20-M01

EMEA-002432-PIP02-20-M01

Jun 24, 2025 - 13:50
 0
EMEA-002432-PIP02-20-M01
EMEA-002432-PIP02-20-M01
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Zessly, infliximab, Da...

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): Zejula, niraparib (to...

Related Posts

Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date of authorisation: 09/11/2017, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 12, 2025  0

Human medicines European public assessment report (EPAR): Supemtek Tetra (previously Supemtek), quadrivalent influenza vaccine (recombinant, prepared in cell culture), Date of authorisation: 16/11/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 22, 2025  0

EMEA-003176-PIP02-22

EMEA-003176-PIP02-22

May 13, 2025  0